Results 231 to 240 of about 7,707 (294)
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Enteric-coated mycophenolate sodium
Expert Opinion on Drug Safety, 2010Mycophenolic acid (MPA) therapy is a fundamental component of most post-transplant immunosuppressive regimens. Side effects, however, are common and frequently necessitate dose reductions or discontinuations.Enteric-coated mycophenolate sodium (EC-MPS) is designed to improve the gastrointestinal (GI) tolerability of MPA.
Klemens, Budde +4 more
openaire +2 more sources
Enteric-Coated Mycophenolate Sodium
Annals of Pharmacotherapy, 2003OBJECTIVE:To review the pharmacology, pharmacokinetics, efficacy, and safety of mycophenolate sodium.DATA SOURCES:Primary literature was obtained via a MEDLINE search (1966–June 2003). Abstracts were obtained from the manufacturer and included in the analysis.STUDY SELECTION AND DATA EXTRACTION:All studies and abstracts evaluating mycophenolate sodium ...
Steven, Gabardi +2 more
openaire +2 more sources
The American Journal of Medicine, 1948
Abstract 1.1. Investigations of enteric-coated drugs have shown that some with coatings which claim to "protect the tablet from gastric secretions" fail as well to disintegrate in any other part of the gastrointestinal tract. 2.2. Other preparations disintegrate in the stomach, and in these instances the enteric coating is of no particular value ...
openaire +2 more sources
Abstract 1.1. Investigations of enteric-coated drugs have shown that some with coatings which claim to "protect the tablet from gastric secretions" fail as well to disintegrate in any other part of the gastrointestinal tract. 2.2. Other preparations disintegrate in the stomach, and in these instances the enteric coating is of no particular value ...
openaire +2 more sources
JAMA: The Journal of the American Medical Association, 1974
ABSTRACT To the Editor.— In a letter by Jansen (226:1361, 1973) commenting on the article titled, "Lipoid Pneumonia Caused by Methenamine Mandelate Suspension," by Timmerman and Schroer (225:1524, 1973), it was implied that methenamine mandelate tablets are available only as entericcoated tablets.
openaire +1 more source
ABSTRACT To the Editor.— In a letter by Jansen (226:1361, 1973) commenting on the article titled, "Lipoid Pneumonia Caused by Methenamine Mandelate Suspension," by Timmerman and Schroer (225:1524, 1973), it was implied that methenamine mandelate tablets are available only as entericcoated tablets.
openaire +1 more source
Enteric-Coated Potassium Supplements
JAMA: The Journal of the American Medical Association, 1974To the Editor.— Despite previous widespread publicity concerning the hazards of enteric-coated potassium supplements, these preparations are still commercially available, prescribed, and dispensed. This was shown recently in a survey that we conducted of 25 pharmacies in the San Francisco metropolitan area.
openaire +1 more source
Self-poisoning with Enteric-coated Aspirin
American Journal of Clinical Pathology, 1983A case of self-poisoning by enteric-coated aspirin tablets is described. Absorption of salicylate was delayed, resulting in serum kinetics different from that obtained with regular aspirin. When the ingested aspirin is enteric coated, the use of Done's nomogram may be inappropriate.
T C, Kwong, J, Laczin, J, Baum
openaire +2 more sources
Enteric Coated Dipropylacetate (Depakine®)
1975Depakine® (sodium di-n-propylacetate, DPA) is a powerful anti-epileptic drug for the treatment of convulsive and non-convulsive generalized epilepsy (Bergamini et al., 1970; de Biolley and Sorel, 1969) as well as for the treatment of focal epilepsy (Meinardi, 1971). It is available in tablets of 300 mg.
A. E. H. Sonnen +2 more
openaire +1 more source